Nature Reviews Drug Discovery

Analysis of phase II and phase III clinical trial terminations from 2013 to 2023

Heather Bowling, Arianna Cocucci, Da Chen Emily Koo et al. May 01, 2026 pp. 345-346 10.1038/d41573-025-00208-6

Biologic degraders push forward in the clinic

Asher Mullard May 01, 2026 pp. 335-339 10.1038/d41573-026-00064-y

FDA new drug approvals in Q1 2026

Paul Verdin May 01, 2026 pp. 342-342 10.1038/d41573-026-00061-1

Where are the women’s health drugs?

Asher Mullard May 01, 2026 pp. 343-344 10.1038/d41573-026-00060-2

Lipid nanoparticles deliver to the pancreas

Alex Eccleston May 01, 2026 pp. 348-348 10.1038/d41573-026-00058-w

FDA approves GLP-1 pill for obesity

Asher Mullard May 01, 2026 pp. 341-341 10.1038/d41573-026-00059-9

Dialling up the circadian clock to target ageing

M. Teresa Villanueva May 01, 2026 pp. 349-349 10.1038/d41573-026-00057-x

ROCK2 is a druggable angiocrine target in liver fibrosis

Isobel Leake May 01, 2026 pp. 350-350 10.1038/d41573-026-00053-1

First-in-class blood–brain barrier shuttle wins FDA nod for Hunter syndrome

Asher Mullard May 01, 2026 pp. 340-340 10.1038/d41573-026-00055-z

Oral macrocyclic IL-23 inhibitor nabs FDA approval for psoriasis

Asher Mullard May 01, 2026 pp. 340-340 10.1038/d41573-026-00054-0

Trikines rewire STAT signalling

Sarah Crunkhorn May 01, 2026 pp. 351-351 10.1038/d41573-026-00052-2

Enhancing CAR-NK cell efficacy in solid tumours

Sarah Crunkhorn May 01, 2026 pp. 351-351 10.1038/d41573-026-00049-x

Exon skipping to treat Rett syndrome

Sarah Crunkhorn May 01, 2026 pp. 351-351 10.1038/d41573-026-00050-4

Targeted degradation of amyloid-β

Sarah Crunkhorn May 01, 2026 pp. 351-351 10.1038/d41573-026-00051-3

Non-incretin approach for weight loss

Sarah Crunkhorn May 01, 2026 pp. 347-347 10.1038/d41573-026-00048-y

Therapeutic targeting of neuroimmune mechanisms in neurodegeneration

Kathryn M. Monroe, Soyon Hong, Joseph W. Lewcock et al. May 01, 2026 pp. 390-405 10.1038/s41573-025-01370-7

Unlocking the potential of disease prevention through regulatory science

Daniel J. O’Connor, Alison C. Cave, Alejandro F. Frangi et al. May 01, 2026 pp. 333-334 10.1038/d41573-026-00016-6

Targeting extrachromosomal DNA in human cancers

Ivy Tsz-Lo Wong, Hyerim Yi, Bruno Melillo et al. May 01, 2026 pp. 374-389 10.1038/s41573-025-01369-0

Strategies for blood–brain barrier rejuvenation and repair

Peter C. Searson, William A. Banks May 01, 2026 pp. 352-373 10.1038/s41573-025-01364-5